Access to medications and medical care after participation in HIV clinical trials: A systematic review of trial protocols and informed consent documents

HIV Clinical Trials

Volumn 10, Issue 1, 2009, Pages 13-24

  Ciaranello, Andrea ^a   Walensky, Rochelle ^a,b,c   Sax, Paul ^b   Chang, Yuchiao ^a   Freedberg, Kenneth ^a,c   Weissman, Joel ^d  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

Clinical trials; HIV; Posttrial services; Trial protocols

Indexed keywords

ANTIRETROVIRUS AGENT; ZIDOVUDINE;

ARTICLE; CLINICAL RESEARCH; CLINICAL TRIAL; DRUG INDUSTRY; FOOD AND DRUG ADMINISTRATION; HEALTH CARE ACCESS; HEALTH CARE DELIVERY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFORMATION SERVICE; INFORMED CONSENT; MEDICAL CARE; MEDICAL DOCUMENTATION; MEDICAL INFORMATION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REGISTER; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

EID: 64949121223     PISSN: 15284336     EISSN: None     Source Type: Journal    
DOI: 10.1310/hct1001-13     Document Type: Article

References (31)

1. Pace C, Grady C, Wendler D, Bebchuk JD, Tavel JA, McNay LA, et al. Post-trial access to tested interventions: The views of IRB/REC chair, investigators, and research participants in a multinational HIV/AIDS study. AIDS Res Hum Retroviruses. 2006;22:837-841.
2. Participants in the 2001 Conference on Ethical Aspects of Research in Developing Countries. Moral standards for research in developing countries: From "reasonable availability" to "fair benefi ts." Hastings Center Report. 2004;34:17-27.
3. Emanuel EJ. Undue inducement: Nonsense on stilts? Am J Bioethics. 2005;5:9-13.
4. GlaxoSmithKline. Clinical trials in the developing world. 2005. Available at: http://www.gsk.com/corporate-responsibility/ Downloads/clinical-trials-in- the-developing- world.pdf. Accessed December 15, 2005.
5. Macklin R. After Helsinki: Unresolved issues in international research. Kennedy Inst Ethics J. 2001;11:17-36.
6. Weijer C, LeBlanc G. The Balm of Gilead: Is the provision of treatment to those who seroconvert in HIV prevention trials a matter of moral obligation or moral negotiation? J Law Med Ethics. 2006;34:793-808.
7. Slack C, Stobie M, Milford C, Lindegger G, Wassenaar D, Strode A, Ijsselmuiden C. Provision of HIV treatment in HIV preventive vaccine trials: A developing country perspective. Soc Sci Med. 2005;60:1197-1208.
8. McMillan JR, Conlon C. The ethics of research related to health care in developing countries. J Med Ethics. 2004;30:204-206.
9. Ananworanich J, Cheunyam T, Teeratakulpisarn S, Boyd MA, Ruxrungtham K, Lange J, et al. Creation of a drug fund for post-clinical trial access to antiretrovirals. Lancet. 2004;364:101-102.
10. Shaffer DN, Yebei VN, Ballidawa JB, Sidle JE, Greene JY, Meslin EM, et al. Equitable treatment for HIV/AIDS clinical trial participants: A focus group study of patients, clinician researchers, and administrators in Western Kenya. J Med Ethics. 2006;32:55-60.
11. El-Sadr WM, Lundgren JD, Neaton JD, Gordin F, Abrams D, Arduino RC, et al. CD4count-guided interruption of antiretroviral treatment. N Engl J Med. 2006;355: 2283-2296.
12. Lundgren JD, Babiker A, El-Sadr W, Emery S, Grund B, Neaton JD, et al. Inferior clinical outcome of the CD4cell count-guided antiretroviral treatment interruption strategy in the SMART study: Role of CD4cell counts and HIV RNA levels during follow-up. J Infect Dis. 2008;197:1145-1155.
13. Department of Health and Human Services. Panel on Antiretroviral Guidelines for Adults and Adolescents: Guidelines for the Use of Antiretroviral Agents in HIV-1 Infected Adults and Adolescents. 2008. Available at: http:// aidsinfo.nih.gov/contentfi les/AdultandAdolescentGL.pdf. Accessed September 15, 2008.
14. World Medical Association. Declaration of Helsinki. 2004. Available at: http://www.wma.net/e/policy/b3.htm. Accessed October 15, 2006.
15. National Institutes of Health. Guidance for addressing the provision of antiretroviral treatment for trial participants following their completion of NIH-funded HIV antiretroviral treatment trials in developing countries: March 16, 2005. Available at: http://grants.nih.gov/grants/guide/ notice-files/NOT-OD- 05-038.html. Accessed December 28, 2006.
16. Council for International Organizations of Medical Sciences. International ethical guidelines for biomedical research involving human subjects (revised, 2002). 1993. Available at: http://www.fhi.org/training/fr/ Retc/pdf-fi les/ cioms.pdf. Accessed January 4, 2007.
17. Joint United Nations Programme on HIV/AIDS (UNAIDS). Ethical Considerations in HIV Preventive Vaccine Research: UNAIDS Guidance Document. Geneva: UNAIDS; 2001.
18. Nuffield Council on Bioethics. The Ethics of Research Related to Healthcare in Developing Countries. London: Nuffield Council on Bioethics; 2002. Available at: http://www.nuffieldbioethics.org/fileLibrary/pdf/errhdc- fullreport001.pdf
19. National Bioethics Advisory Commission. When research is concluded-access to the benefits of research by participants, communities, and countries. In: Ethical and Policy Issues in International Research: Clinical Trials in Developing Countries. Washington, DC: US Government Printing Offi ce; 2001.
20. United States Department of Health and Human Services. Common Rule: 45 Code of Federal Regulations (CFR) 46. 2005. Available at: http://www.hhs.gov/ ohrp/ humansubjects/guidance/45cfr46.htm. Accessed January 4, 2007.
21. United States Public Health Service. Consultation on international collaborative HIV research. Law Med Health Care. 1991;259:3-4.
22. US Food and Drug Administration. CDER Handbook. 2008. Available at: http://www.fda.gov/cder/handbook/. Accessed September 15, 2008.
23. US Food and Drug Administration. Center for Drug Evaluation and Research: Drugs used in the treatment of HIV infection. 2006. Available at: http://www.fda.gov/oashi/ aids/virals.html. Accessed December 15, 2006.
24. National Institutes of Health. Clinicaltrials.gov. 2008. Available at: http://www.clinicaltrials.gov. Accessed December 15, 2006.
25. Adult AIDS Clinical Trials Group. Protocol Specifi c Web Pages. Available at: http://www.aactg.com/members/ reports/aactprot.htm. Accessed December 15, 2006.
26. Merritt M, Grady C. Reciprocity and post-trial access for participants in antiretroviral therapy trials. AIDS. 2006;20:1791-1794.
27. Hutt LE. Freebies for subject 641: A discussion of the ethical prospect of providing drug trial subjects with posttrial access to the drug tested-a Canadian perspective. Health Law J. 1998;6(Spec No):169-187.
28. Grady C. The challenge of assuring continued post-trial access to benefi cial treatment. Yale J Health Policy Law Ethics. 2005;5:425-435.
29. US Department of Health and Human Services. Office for Human Research Protections (OHRP): Assurances. 2006. Available at: http://www.hhs.gov/ohrp/ assurances/ assurances-index.html. Accessed August 14, 2008.
30. US Food and Drug Administration. Information Sheets (Guidance for Institutional Review Boards and Clinical Investigators, 1998 Update). A Guide to Informed Consent. 1998. Available at: http://www.fda.gov/oc/ohrt/IRBs/ informedconsent.html. Accessed August 13, 2008.
31. Emanuel EJ, Wendler D, Grady C. What makes clinical research ethical? JAMA. 2000;283:2701-2711.